Margarida Azevedo, MSc,  —

The first patients to complete a Phase 2 clinical trial have chosen to continue treatment in an open-label extension (OLE) study of Amylyx Pharmaceuticals‘ investigative therapy AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is an oral combination of two small molecules, sodium phenylbutyrate (PB) and tauroursodeoxycholic acid…

EH301, Elysium Health‘s investigational therapy for amyotrophic lateral sclerosis (ALS), was recently granted orphan drug status by the U.S. Food and Drug Administration. Elysium’s application for orphan drug designation included data from a 2017 double-blind, placebo-controlled European pilot study in humans. To expand on the results of the pilot study,…

BrainStorm Cell Therapeutics is adding Canadians to a Phase 3 U.S. clinical trial of its ALS stem cell therapy NurOwn. It decided to add the Canadians when a number of them expressed interest in participating, BrainStorm said. The trial (NCT03280056) is investigating the safety and effectiveness of repeated doses…

Prothena and Celgene are teaming up to develop treatments for a range of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The collaboration will focus on therapies that can target proteins such as tau and TDP-43 that scientists have linked to these disorders. “The programs we have chosen to collaborate…

Three organizations that are fighting neurodegenerative disorders have teamed up to challenge researchers around the world to come up with new treatment approaches. The ALS Association, the Huntington’s Disease Society of America (HDSA) and Teva Pharmaceuticals have started the crowdsourcing effort, known as the Teva CNS Target Identification…

The Montreal Neurological Institute of McGill University and Thermo Fisher Scientific have recently partnered to accelerate the understanding of neurological disease by focusing on about 30 proteins associated with amyotrophic lateral sclerosis (ALS) and other brain diseases. The collaboration is part of…

Orangetheory fitness members across the United States and Canada plan to raise $2 million for Augie’s Quest to cure ALS, an organization supporting research into a cure for amyotrophic lateral sclerosis (ALS). Money raised this year will go to help advance a promising potential ALS treatment, AT-1501,…

Sangamo Therapeutics and Pfizer will work together on gene therapies they hope will overcome mutations that cause ALS and frontotemporal lobar degeneration. Gene therapy works by delivering a healthy copy of a malfunctioning gene to a patient. The therapy that Sangamo is developing replaces a faulty C9orf72 gene. It consists…

Throughout 2017, ALS News Today brought you daily coverage of amyotrophic lateral sclerosis (ALS)-related advocacy events, clinical studies, and the latest research updates. We have compiled a top 10 list of the most-read ALS news stories of that year, with a brief description of what made them interesting and…

Two young companies, QurAlis and Kernal Biologics, are winners of the Amgen Golden Tickets for innovative bioscience projects — in this case, work that might lead to better treatments in amyotrophic lateral sclerosis (ALS) and cancer immunotherapy, Amgen and LabCentral announced. QurAlis is developing therapies for three different forms of…